Phibro Animal Health (NASDAQ:PAHC) Stock Price Up 5.2% – Should You Buy?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s share price traded up 5.2% on Friday . The stock traded as high as $38.38 and last traded at $38.24. 21,217 shares traded hands during trading, a decline of 93% from the average daily volume of 294,857 shares. The stock had previously closed at $36.35.

Analyst Upgrades and Downgrades

PAHC has been the subject of a number of analyst reports. Wall Street Zen cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Citigroup lowered their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Finally, Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $42.50.

Phibro Animal Health Price Performance

The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The stock’s 50-day moving average price is $34.04 and its 200-day moving average price is $42.32. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.14. The firm had revenue of $396.75 million during the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health had a net margin of 6.57% and a return on equity of 39.28%. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 3.33 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be paid a $0.12 dividend. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio is 20.60%.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently added to or reduced their stakes in PAHC. 1620 Investment Advisors Inc. boosted its holdings in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares during the period. KBC Group NV purchased a new stake in Phibro Animal Health in the 1st quarter worth approximately $29,000. Rothschild Investment LLC boosted its stake in Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after buying an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in Phibro Animal Health in the third quarter valued at approximately $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.